A!smaller!single>arm!phase!2!study!of!the!Spanish!GELTAMO!group!showed!promising!results!
with!Rituximab!and!Bendamustine.!!
!
Early! progression! of! the! disease! predicts! shorter! survival! in! MALT! lymphoma! patients!
receiving!systemic!treatment.!However,!there!are!no!widely!accepted!prognostic!indices!to!
be! used! at! diagnosis! for! outcome! prediction! in! MALT! lymphoma.! The! IELSG! investigators!
used! the! IELSG19! study! database! to! develop! a! specific! prognostic! tool! to! personalize! and!
optimize! lymphoma! treatment! of! patients! with! MALT! lymphoma.! This! simple! prognostic!
index! (named! MALT>IPI)! is! based! on! 3! clinical! features,! namely,! age! ≥70! years,! Ann! Arbor!
stage!III!or!IV,!and!elevated!LDH!level.!!
!
Targeted!therapies!have!also!shown!promising!results!and!a!number!of!novel!chemotherapy!
–free!approaches!are!under!evaluation.!!
!
References:(
1. Alderuccio!JP,!Zhao!W,!Desai!A!et!al.!Short!survival!and!frequent!transformation!in!extranodal!
marginal! zone! lymphoma! with! multiple! mucosal! sites! presentation.! Am! J! Hematol.! 2019!
May;94(5):585>596.!!
2. Arcaini! L,! Vallisa! D,! Rattotti! S! et! al.! Antiviral! treatment! in! patients! with! indolent! B>cell!
lymphomas!associated!with!HCV!infection:!a!study!of!the!Fondazione!Italiana!Linfomi.!Ann!Oncol!
2014;!1404>10.!!
3. Arcaini! L,! Rossi! D,! Paulli! M.! Splenic! marginal! zone! lymphoma:! from! genetics! to! management.!
Blood.!!2016;127:2072>81.!!
4. Bertoni! F,! Rossi! D,! Zucca! E.! Recent! advances! in! understanding! the! biology! of! marginal! zone!
lymphoma.!F1000Res.!2018;7:406.!doi:!10.12688/f1000research.13826.1.!eCollection!2018.!!
5. 14.Conconi! A,! Franceschetti! S,! Aprile! von! Hohenstaufen! K,! et! al.! Histologic! transformation! in!
marginal!zone!lymphomas.!Ann!Oncol.!2015;26(11):2329>2335.!!
6. Conconi!A,!Thieblemont!C,!Cascione!L!et!al.!Early!progression!of!disease!predicts!shorter!survival!
in! MALT! lymphoma! patients! receiving! systemic! treatment.! Haematologica.! 2020;! 105:! 2592>
2597.!doi:!10.3324/haematol.2019.237990.!!
7. Noy! A,! de! Vos! S,! Thieblemont! C! et! al.! Targeting! Bruton! tyrosine! kinase! with! ibrutinib! in!
relapsed/refractory!marginal!zone!lymphoma.!Blood!2017;!129:!2224>2232.!!
8. Raderer!M,!Kiesewetter!B,!Ferreri!AJ.!Clinicopathologic!characteristics!and!treatment!of!marginal!
zone! lymphoma! of! mucosa>associated! lymphoid! tissue! (MALT! lymphoma).! CA! Cancer! J! Clin!
2016;!66:!153>!171.!!
9. Salar!A,!Domingo>Domenech!E,!Panizo!C!et!al.!Long>term!results!of!a!phase!II!study!of!rituximab!
and! bendamustine! for! mucosa>associated! lymphoid! tissue! lymphoma.! Blood! 2017;! 130:1772>
1774.!!
10. Spina! V,! Rossi! D.! Molecular! pathogenesis! of! splenic! and! nodal! marginal! zone! lymphoma.! Best!
Pract!Res!Clin!Haematol.!2017;!30:5>12.!!
11. Teckie!S,!Qi!S,!Chelius!M,!et!al.!Long>term!outcome!of!487!patients!with!early>stage!extra>nodal!
marginal!zone!lymphoma.!Ann!Oncol.!2017;28:1064>1069.!!
12. Thieblemont! C,! Cascione! L,! Conconi! A! et! al.! A! MALT! lymphoma! prognostic! index.! Blood! 2017;!
130:!1409>!1417.!!
13. Zucca! E,! Bertoni! F,! Vannata! B,! Cavalli! F.! Emerging! role! of! infectious! etiologies! in! the!
pathogenesis!of!marginal!zone!B>cell!lymphomas.!Clin!Cancer!Res.!2014;.20:5207>16.!!
14. Zucca! E,! Bertoni! F.! The! Spectrum! of! MALT! lymphoma! at! different! sites:! biological! and!
therapeutic!relevance.!Blood!2016;!127:!2082>2092.!!
15. Zucca!E,!Conconi!A,!Martinelli!G!et!al.!Final!Results!of!the!IELSG>19!Randomized!Trial!of!Mucosa>!
Associated! Lymphoid! Tissue! Lymphoma:! Improved! Event>Free! and! Progression>Free! Survival!
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES